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Abstract Transaldolase (TALDO) deficiency is a rare meta-
bolic disease in the pentose phosphate pathway, which man-
ifests as a severe, early-onset multisystem disease. The body
fluids of affected patients contain increased polyol concentra-
tions and seven-carbon chain carbohydrates. We report the
molecular and clinical findings in two recently diagnosed
transaldolase-deficient children, both presented at birth. Dur-
ing infancy, they presented thin skin with a network of visible
vessels, spider telangiectasias and multiple haemangiomas.
Such unusual skin changes are characteristic of liver damage.
Later, the patients developed rapidly progressive nodular liver
fibrosis, tubulopathy and severe clotting disturbances. The
clinical features of these patients were in line with previously
studied patients with transaldolase deficiency. The diagnosis
was established by detecting high concentrations of erythritol,
ribitol, arabitol, sedoheptitol, perseitol, sedoheptulose and
sedoheptulose-7-phosphate in the urine. Detection was made
by gas chromatography and liquid chromatography-tandem
mass spectrometry and then confirmed by molecular analysis
of the TALDO gene. Conclusion: Transaldolase deficiency, a
rare early-onset multisystem disease, should be considered by
neonatologists, paediatricians, hepatologists and nephrolo-
gists in the differential diagnosis of patients presenting
hepatosplenomegaly, thrombocytopenia, anaemia, bleeding
diathesis, liver failure and tubulopathy.
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Introduction
Transaldolase (TALDO) deficiency (OMIM 606003) is an in-
born error of the pentose phosphate pathway, which is a severe,
early-onset multisystem disease. The body fluids of affected
patients contain increased concentrations of polyol, heptulose,
sedoheptulose, mannoheptulose and sedoheptulose-7P, mostly
in the urine [8].
Patients present severe symptoms during the neonatal pe-
riod, and in almost all cases, some signs were already noted
prenatally. The leading symptoms in transaldolase-deficient
patients are anaemia, bleeding problems with thrombocytope-
nia, hepatosplenomegaly, nodular progressive hepatic fibrosis
and later on nephropathy. To date, 23 patients from 13 families
have been described [1, 3, 6–9, 11]. The majority of patients
have consanguineous parents.
We present the clinical biochemical and molecular findings
of two recently diagnosed transaldolase-deficient patients
from two unrelated Polish families. Two boys, currently 2
and 3 years old, presented intrauterine growth retardation
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(IUGR), ascites and oligoamnios. Postnatally, they presented
anaemia, bleeding diathesis, hepatosplenomegaly and liver
involvement. In contrast with their physical development,
psychomotor development was normal. Both presented a
characteristic of thin skin with a network of visible vessels,
spider telangiectasias, and multiple haemangiomas. These
skin changes, characteristic of liver damage, immediately
made us consider transaldolase deficiency (Fig 1).
Materials and methods
Patient 1 (KL)
A boy, the first born child of unrelated parents, was noted to
have oligoamnios as well as foetal growth retardation. He was
delivered by caesarean section at 41 weeks. At birth, the boy
presented low body weight (2,150 g), hepatosplenomegaly,
anaemia and clotting diathesis.
At the age of 1 month, he was hospitalised because of
hepatosplenomegaly, anaemia and failure to thrive (low body
mass). At that time, thin skin with a network of visible vessels,
spider angiomas and multiple haemangiomaswere noted. Ad-
ditional investigations revealed blood clotting disturbances,
prolonged prothrombin time (PT), activated partial thrombo-
plastin time (APTT), deficiency in factors XI XII, elevated
transaminases, hypoproteinemia, anaemia (Hb 7,3, E 2,97),
thrombocytopenia and nodular changes in the liver. These
features suggested TALDO deficiency, and therefore, sugars
and polyols were determined. Elevated excretion of erythritol,
ribitol, arabitol, sedoheptitol, perseitol, sedoheptulose and
sedoheptulose-7P in the urine was detected by gas chromatog-
raphy (GC) and liquid chromatography-tandemmass spectrom-
etry (LC-MS/MS; Table 1), which is indicative of TALDO
deficiency [5, 8, 9]. A homozygous deletion (c.462-
174_981+53del) in the TALDO gene was expected because of
the fact that exon 5 could not be amplified by PCR in contrast to
all other exons. The deletion was confirmed by long-range PCR
followed by sequencing of the region of exons 4 to 8. This
revealed a deletion of approximately 1.3 kb comprising the 3′-
end of intron 4 and the 5′-end of intron 7.
Currently, the boy is 3 years old. He presents anaemia,
bleeding diathesis, thrombocytopenia, elevated transaminases,
signs of tubulopathy, renal tubular dysfunction (proteinuria,
aminoaciduria, uricuria and hypercalciuria, renal acidosis) and
an increased number of nodular changes in his liver.
Patient 2 (SA)
He is the first born of young non-consanguineous parents.
During pregnancy, growth retardation of the foetus was noted;
ultrasonography revealed fluid in the pericardium and abdom-
inal cavity. Labour at 37 weeks was uncomplicated; his birth
weight was 2,410 g. During the neonatal period, he presented
an enlarged spleen and liver, cryptorchismus, skin changes in
the form of visibly dilated vessels, spider angiomas and cav-
ernous haemangiomas. Laboratory investigations showed
anaemia, thrombocytopenia, lymphopenia, blood clotting dis-
turbances, PT, APTT, deficiency in atythrombin III, elevated
bilirubin and gamma-glutamyltransferase, mildly elevated
transaminases and elevated alpha-fetoprotein. At the age of
6 months, renal calculus was found; few small calculi in both
kidneys were detected by ultrasound. Magnetic resonance of
the liver revealed multiple fibrotic nodular changes and mal-
formation of the left branch of the hepatic portal vein.
Fig. 1 Skin changes characteristic of liver damage that immediately
made us consider transaldolase deficiency
Table 1 Urinary concentrations of polyols and seven-carbon sugars of















Erythritolb 687 89–158 360 76–192
Arabitolb 588 51–99 354 52–88
Ribitolb 432 10–17 209 9–24
Sedoheptitolb 13 <1 ↑ <1
Perseitolb 67 <1 nd <1
Sedoheptuloseb ≥2,500 <9 ↑ <9
Mannoheptuloseb Disturbed <3 nd <3
Sedoheptulose-7Pb 1.29 <0.12 3.71 <0.12
Values in italics are elevated compared with age-related reference values.
Disturbed denotes that mannoheptulose is not quantitative due to very
high excretion of sedoheptulose
nd not done
aMetabolites were measured in urine spotted on filter paper and after-
wards extracted with water. Some sugars are not stable on filter paper;
therefore, the actual concentrations might have been higher
b LC/MS-MS method [10]
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At the age of 15 months, urinary sugars and polyols were
measured using GC, and the profile suggested transaldolase
deficiency.
Molecular analysis revealed two mutations, (c.575G>A;
p.(Arg192His) and (c.462-174_981+53del), in the TALDO
gene. Both parents are carriers of one of the described muta-
tions, confirming compound heterozygosity in the child. The
c.575G>A mutation had been found before in patients affect-
ed with TALDO deficiency [2]. The second allele initially
remained unnoticed, but, since tests in our laboratory had
previously detected homozygous deletion in the DNA of
patient 1 (this report), we decided to investigate, by means
of long-range PCR, whether this deletion might also be pres-
ent in heterozygous form in the DNA of patient 2. This
confirmed the diagnosis.
Currently, the patient is 2 years old and has severe clotting
disturbances as well as anaemia, thrombocytopenia and pan-
cytopenia. He also developed tubulopathy and numerous cal-
culi in both kidneys. The progress of liver damage and renal
involvement is dynamic and suggests a poor outcome.
Discussion
TALDO deficiency results in a severe metabolic distur-
bance which affects foetal development and produces
characteristic signs such as placental overgrowth, amniotic
and foetal body fluid imbalance, and intrauterine growth
retardation [1, 3, 6–8, 11]
Prenatally, our two patients with TALDO deficiency al-
ready presented intrauterine growth retardation, ascites and
oligoamnios. Postnatally, they presented anaemia, bleeding
diathesis, hepatosplenomegaly, liver involvement and overall
poor physical development. Their mental development is
normal.
The clinical features were characteristic of TALDO defi-
ciency, and diagnosis was confirmed via biochemical and
molecular methods. In the second case, we first detected, by
way of Sanger sequencing of PCR products, only one hetero-
zygous missense mutation. Heterozygous deletion could only
be detected because of a detection in another Polish patient
(i.e. patient 1 in this report)—a homozygous deletion that was
confirmed by long-range PCR. Usually, heterozygous dele-
tions are missed since most laboratories use direct DNA
sequence analysis of PCR products, and this technique cannot
detect copy number variations (e.g. heterozygous deletions of
exons or duplications). This means that further work is needed
if there is a strong suspicion based on clinical characteristics or
biochemical basis. Also, if none or only one of the mutations
is detected, then further work is needed. This could include
mRNA analysis and/or specific tests for the presence of ge-
nomic deletions, such as multiplex probe amplification tests
or, if available, long-range PCR.
Both patients presented a characteristic of thin skin with a
network of visible vessels, spider angiomas and multiple
haemangiomas (Fig. 1). Curtis laxa or dysmorfismdescribed
by other authors was not present in our patients [3, 7]. In
patient 2, liver vessel malformation and skin haemangiomas
(blood vessel malformations; Fig. 2) were present. These
skin changes were observed in other patients [3, 6], and it
seems to be characteristic of patients with transaldolase de-
ficiency. Spider angiomas and blood vessel dilatation are
related to significant damage of the liver. Spider angiomas
are present in adult patients when their liver cannot detoxify
oestrogen from the blood, resulting in high levels of
oestrogen [4]. In cases of TALDO deficiency, liver damage
begins at the foetal stage, resulting in clotting disturbances,
elevated transaminases, hypoalbuminemia and characteris-
tic changes of skinvessels in thenewborn.The latter suggests
a toxic impact of accumulated sugars andpolyols on the liver,
which starts on early foetal life. Patients with TALDO defi-
ciency are already born with advanced disease primarily
affecting not only the liver but also the kidneys, vessels,
and other systems. However, in the differential diagnosis,
syndromes with liver failure and tubulopathy like
tyrosinemia type I and Fanconi–Bickel syndrome could be
considered.
The development of tubulopathy and, in the case of the
second patient, nephrolithiasis is probably due to the toxic
effect of sugars, sugar phosphates and polyols on the proximal
tubules, leading to kidney failure [5].
Haemangiomas present in our and other patients may
be secondary to the disturbed placental formation and
function [2]. Placental abnormalities in TALDO deficien-
cy have been described by other authors [1, 3, 6, 7, 11].
Symptomatic treatment can be proposed. Liver transplan-
tation in the early stage of the disease could perhaps be
useful.
Fig 2 Skin haemangioma in patient with transaldolase deficiency
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